ESMO Breast Cancer 2026 Highlights: Saci-IO HR+ - Top-Institutions - MDSpire

ESMO Breast Cancer 2026 Highlights: Saci-IO HR+

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber/Harvard Cancer Center
    Dana-Farber/Harvard Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Breast Oncology

  • #2

    University of Chicago Medicine Comprehensive Cancer Center
    University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois

    Key Differentiators

    • Breast Medical Oncology

Original Source(s)

ESMO Breast Cancer 2026 Highlights: Saci-IO HR+

  • June 26, 2026

Related Content

Rebuilding cancer care in post-conflict Syria: restoring continuity across the cancer care continuum

Joseph Fraumeni Jr., pioneering cancer genetics researcher, devoted his life to families like mine

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study